Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma
ConditionThymoma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorSun Yat-sen University
About this trial
This study aims to assess the efficacy of methylprednisolone combined with concurrent chemoradiotherapy in treating unresectable or recurrent thymoma.
Eligibility criteria
Qualifiers
Histologically confirmed type AB or B1-3 thymoma.
Measurable Disease: Patients must have measurable disease as defined by RECIST (Response Evaluation Criteria in Solid Tumors).
Unresectable or recurrent thymoma, with the tumor confined to the chest and neck area.
Between the ages of 18 and 70 years, regardless of sex.
Disqualifiers
Contraindications to Methylprednisolone.
History of or Concurrent Malignancy.
Active infection, myocardial infarction within the last 6 months or symptomatic heart disease.
Pregnant or Lactating Women.
Trial design
Treatments tested in this trial
- Radiotherapy
- Concurrent chemotherapy
- Methylprednisolone
Treatment groups
45 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov